Repeat stereotactic body radiation therapy for patients with pulmonary malignancies who had previously received SBRT to the same or an adjacent tumor site

被引:28
|
作者
Valakh, Vladimir [1 ]
Miyamoto, Curtis [1 ]
Micaily, Bizhan [1 ]
Chan, Philip [1 ]
Neicu, Toni [1 ]
Li, Shidong [1 ]
机构
[1] Temple Univ, Sch Med, Dept Radiat Oncol, Philadelphia, PA 19122 USA
关键词
Lung cancer; recurrence; reirradiation; stereotactic body radiation therapy; stereotactic radiotherapy; CELL LUNG-CANCER; RADIOTHERAPY; REIRRADIATION; RECURRENT;
D O I
10.4103/0973-1482.126481
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: Retrospective analysis of patients with recurrences at or closely adjacent to the site of prior lung stereotactic body radiation therapy (SBRT) who received repeat SBRT. Materials and Methods: Nine patients with non-small cell lung cancer (n = 8) or oligometastatic colonic adenocarcinoma (n = 1) were treated with image-guided lung SBRT to a median of 60 Gy (range, 30-60) in a median of 3 fractions (3-5). Patients developed in-field relapse (n = 3) or recurrence adjacent (<= 3.5 cm away) to the previous tumor location (n = 6) and received 2nd lung SBRT to a median of 60 Gy. Results: Median follow-up after 2nd SBRT was 22 months (4-40). All completed prescribed course of repeat SBRT and acute toxicity was limited. There was no grade >3 late toxicity. 3 (33.3%) patients developed Grade 3 late reactions: 2 pulmonary and 1 chest wall pain. Late pulmonary toxicity included 2 (22.2%) patients with Grade 3 and 3 (33.3%) with Grade 2. One patient (11.1%) had late Grade 3 and 1 (11.1%) Grade 2 chest wall pain. 1 (11.1%) developed Grade 2 late brachial plexopathy. No myelopathy was observed. Two patients developed progression of tumors treated by 2nd SBRT. Local recurrence free survival and overall survival was 75% and 68.6%, respectively at 2 years. Relative volume of ipsilateral lung receiving 5 Gy (V5) and V10 were lower for 2nd SBRT. Conclusion: Repeat image-guided SBRT for patients with small peripheral recurrences was feasible and severe toxicity was not observed. Additional studies are needed to evaluate the safety and efficacy of lung reirradiation using 2nd SBRT.
引用
收藏
页码:680 / 685
页数:6
相关论文
共 50 条
  • [21] Stereotactic body radiation therapy (SBRT) delays the emergence of castration resistance in patients with oligometastatic prostate cancer
    Martinez-Fernandez, M. I.
    Perez Gracia, J. L.
    Gil-Bazo, I.
    Martinez-Monge, R.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2016, 18 (07) : 743 - 747
  • [22] Stereotactic body radiation therapy (SBRT) in patients with hepatocellular cancer-a narrative review and expert opinion
    Gerum, Sabine
    Grambozov, Brane
    Roeder, Falk
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2024, 15 (04) : 1880 - 1892
  • [23] Stereotactic Body Radiation Therapy as Salvage for Intrathoracic Recurrence in Patients With Previously Irradiated Locally Advanced Non-Small Cell Lung Cancer
    Parks, Jason
    Kloecker, Goetz
    Woo, Shiao
    Dunlap, Neal E.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2016, 39 (02): : 147 - 153
  • [24] A Phase 2 Study of Post-Operative Stereotactic Body Radiation Therapy (SBRT) for Solid Tumor Spine Metastases
    Redmond, Kristin J.
    Sciubba, Daniel
    Khan, Majid
    Gui, Chengcheng
    Lo, Sheng-fu Larry
    Gokaslan, Ziya L.
    Leaf, Brianne
    Kleinberg, Lawrence
    Grimm, Jimm
    Ye, Xiaobu
    Lim, Michael
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 106 (02): : 261 - 268
  • [25] Risk of Severe Toxicity According to Site of Recurrence in Patients Treated With Stereotactic Body Radiation Therapy for Recurrent Head and Neck Cancer
    Ling, Diane C.
    Vargo, John A.
    Ferris, Robert L.
    Ohr, James
    Clump, David A.
    Yau, Wai-Ying Wendy
    Duvvuri, Umamaheswar
    Kim, Seungwon
    Johnson, Jonas T.
    Bauman, Julie E.
    Branstetter, Barton F.
    Heron, Dwight E.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 95 (03): : 973 - 980
  • [26] The histologic effects of neoadjuvant stereotactic body radiation therapy (SBRT) followed by pulmonary metastasectomy-rationale and protocol design for the Post SBRT Pulmonary Metastasectomy (PSPM) trial
    Begum, Housne
    Swaminath, Anand
    Lee, Yung
    Fahim, Christine
    Bramson, Jonathan
    Naqvi, Asghar
    Shargall, Yaron
    Finley, Christian
    Hanna, Wael
    Agzarian, John
    TRANSLATIONAL CANCER RESEARCH, 2022, 11 (04) : 918 - +
  • [27] Management of Bronchial Adenoma/Ciliated Muconodular Papillary Tumor with Definitive Stereotactic Body Radiation Therapy (SBRT): A Case Report
    Maroongroge, Sean
    Weissferdt, Annikka
    Buszek, Samantha
    Rice, David C.
    Smith, Benjamin D.
    Gandhi, Saumil J.
    CLINICAL LUNG CANCER, 2022, 23 (05) : E335 - E338
  • [28] Stereotactic body radiation therapy for the primary tumor and oligometastases versus the primary tumor alone in patients with metastatic pancreatic cancer
    Jiang, Lingong
    Ye, Yusheng
    Feng, Zhiru
    Liu, Wenyu
    Cao, Yangsen
    Zhao, Xianzhi
    Zhu, Xiaofei
    Zhang, Huojun
    RADIATION ONCOLOGY, 2024, 19 (01)
  • [29] Clinical outcomes of patients with malignant lung lesions treated with stereotactic body radiation therapy (SBRT) in five fractions
    Ren, Hua
    Blanco, Angel I.
    Blackmon, Shanda
    Paulino, Arnold C.
    Chiang, Stephen B.
    Butler, E. Brian
    Teh, Bin S.
    JOURNAL OF RADIATION ONCOLOGY, 2012, 1 (01) : 57 - 63
  • [30] Impact of Pretreatment Interstitial Lung Disease on Radiation Pneumonitis and Survival in Patients Treated With Lung Stereotactic Body Radiation Therapy (SBRT)
    Glick, Daniel
    Lyen, Stephen
    Kandel, Sonja
    Shapera, Shane
    Le, Lisa W.
    Lindsay, Patricia
    Wong, Olive
    Bezjak, Andrea
    Brade, Anthony
    Cho, B. C. John
    Hope, Andrew
    Sun, Alexander
    Giuliani, Meredith
    CLINICAL LUNG CANCER, 2018, 19 (02) : E219 - E226